{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:50:42Z","timestamp":1768297842505,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12010-024-05107-x","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T08:06:05Z","timestamp":1734595565000},"page":"2180-2196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Construction and Expression of Fc-FGF21 by Different Expression Systems and Comparison of Their Similarity and Difference with Efruxifermin by In Vitro and In Vivo Studies"],"prefix":"10.1007","volume":"197","author":[{"given":"Xujia","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuehua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaokang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuobing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Goldring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3584-6873","authenticated-orcid":false,"given":"Mu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"5107_CR1","doi-asserted-by":"crossref","unstructured":"Harrison, S. A., et al. (2021). Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nature Medicine, 27(7), 1262\u20131271.","DOI":"10.1038\/s41591-021-01425-3"},{"key":"5107_CR2","doi-asserted-by":"crossref","unstructured":"Kokkorakis, M., et al. (2024). Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges. Metabolism, 154, 155835.","DOI":"10.1016\/j.metabol.2024.155835"},{"key":"5107_CR3","doi-asserted-by":"crossref","unstructured":"Borozan, S., et al. (2024). Metabolic dysfunction-associated steatohepatitis and cardiovascular disease prevention: Is resmetirom useful? Current Vascular Pharmacology.","DOI":"10.2174\/0115701611340703240809044916"},{"key":"5107_CR4","doi-asserted-by":"crossref","unstructured":"Karim, G., & Bansal, M. B. (2023). Resmetirom: An orally administered, smallmolecule, liver-directed, beta-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.  touchREVIEWS in Endocrinology, 19(1), 60\u201370.","DOI":"10.17925\/EE.2023.19.1.60"},{"issue":"7","key":"5107_CR5","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3390\/cancers12071714","volume":"12","author":"B Smeuninx","year":"2020","unstructured":"Smeuninx, B., Boslem, E., & Febbraio, M. A. (2020). Current and future treatments in the fight against non-alcoholic fatty liver disease. Cancers (Basel), 12(7), 1714.","journal-title":"Cancers (Basel)."},{"key":"5107_CR6","doi-asserted-by":"crossref","unstructured":"Bhandari, P., et al. (2022). Nonalcoholic fatty liver disease: Could it be the next medical tsunami? Cureus, 14(4), e23806.","DOI":"10.7759\/cureus.23806"},{"key":"5107_CR7","doi-asserted-by":"crossref","unstructured":"Kaufman, A., et al. (2020). AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in Type 2 Diabetes Patients. Cell Reports Medicine, 1(4), 100057.","DOI":"10.1016\/j.xcrm.2020.100057"},{"key":"5107_CR8","doi-asserted-by":"crossref","unstructured":"Flippo, K. H., & Potthoff, M. J. (2021). Metabolic messengers: FGF21. Nature Metabolism, 3(3), 309\u2013317.","DOI":"10.1038\/s42255-021-00354-2"},{"key":"5107_CR9","doi-asserted-by":"crossref","unstructured":"Stanislaus, S., et al. (2017). A Novel Fc-FGF21 with improved resistance to proteolysis, increased affinity toward beta-Klotho, and enhanced efficacy in mice and cynomolgus monkeys. Endocrinology. 158(5), 1314\u20131327.","DOI":"10.1210\/en.2016-1917"},{"key":"5107_CR10","doi-asserted-by":"crossref","unstructured":"Harrison, S. A., et al. (2023). A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Reports, 5(1), 100563.","DOI":"10.1016\/j.jhepr.2022.100563"},{"key":"5107_CR11","doi-asserted-by":"crossref","unstructured":"Rosenstock, M., et al. (2023). The Novel GlycoPEGylated FGF21 analog pegozafermin activates human FGF receptors and improves metabolic and liver outcomes in diabetic monkeys and healthy human volunteers. Journal of Pharmacology and Experimental Therapeutics. 387(2), 204\u2013213.","DOI":"10.1124\/jpet.123.001618"},{"key":"5107_CR12","doi-asserted-by":"crossref","unstructured":"Sanyal, A., et al. (2019). Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet, 392(10165), 2705\u20132717.","DOI":"10.1016\/S0140-6736(18)31785-9"},{"key":"5107_CR13","doi-asserted-by":"crossref","unstructured":"Le, C. T., et al. (2018). LY2405319, an analog of fibroblast growth factor 21 ameliorates alpha-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice. PLoS One, 13(2), e0192146.","DOI":"10.1371\/journal.pone.0192146"},{"key":"5107_CR14","doi-asserted-by":"crossref","unstructured":"Talukdar, S., et al. (2016). A Long-Acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metabolism, 23(3), 427\u201340.","DOI":"10.1016\/j.cmet.2016.02.001"},{"key":"5107_CR15","doi-asserted-by":"crossref","unstructured":"Raptis, D. D., Mantzoros, C. S., & Polyzos, S. A. (2023). Fibroblast growth factor-21 as a potential therapeutic target of nonalcoholic fatty liver disease. Therapeutics and Clinical Risk Management, 19, 77\u201396.","DOI":"10.2147\/TCRM.S352008"},{"key":"5107_CR16","doi-asserted-by":"crossref","unstructured":"Dumont, J., et al. (2015). Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Critical Reviews in Biotechnology, 36(6), 1110\u20131122.","DOI":"10.3109\/07388551.2015.1084266"},{"key":"5107_CR17","doi-asserted-by":"crossref","unstructured":"Zhang, M., et al. (2024). Advances in serum-free media for CHO cells: From traditional serum substitutes to microbial-derived substances. Biotechnology Journal, 19(6), e2400251.","DOI":"10.1002\/biot.202400251"},{"key":"5107_CR18","doi-asserted-by":"crossref","unstructured":"Zeh, N., et al. (2024). The new frontier in CHO cell line development: From random to targeted transgene integration technologies. Biotechnology Advances, 75, 108402.","DOI":"10.1016\/j.biotechadv.2024.108402"},{"key":"5107_CR19","doi-asserted-by":"crossref","unstructured":"Liu, S., et al. (2024). Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells. Molecular Therapy, 32(1), 74\u201383.","DOI":"10.1016\/j.ymthe.2023.11.022"},{"key":"5107_CR20","doi-asserted-by":"crossref","unstructured":"Tan, E., et al. (2021). HEK293 cell line as a platform to produce recombinant proteins and viral vectors. Frontiers in Bioengineering and Biotechnology, 9, 796991.","DOI":"10.3389\/fbioe.2021.796991"},{"key":"5107_CR21","doi-asserted-by":"crossref","unstructured":"Fitzpatrick, D. P., et al. (2007). Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label-free LC\/MS-based protein quantification method. Proteomics: Clinical Applications, 1(3), 246\u201363.","DOI":"10.1002\/prca.200600768"},{"key":"5107_CR22","doi-asserted-by":"crossref","unstructured":"Wang, M., et al. (2008). Label-free mass spectrometry-based protein quantification technologies in proteomic analysis. Briefings in Functional Genomics and Proteomics, 7(5), 329\u201339.","DOI":"10.1093\/bfgp\/eln031"},{"key":"5107_CR23","doi-asserted-by":"crossref","unstructured":"Micanovic, R., et al. (2009). Different roles of N- and C- termini in the functional activity of FGF21. Journal of Cellular Physiology, 219(2), 227\u201334.","DOI":"10.1002\/jcp.21675"},{"key":"5107_CR24","doi-asserted-by":"crossref","unstructured":"Rubino, D. M., et al. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA, 327(2), 138\u2013150.","DOI":"10.1001\/jama.2021.23619"},{"key":"5107_CR25","doi-asserted-by":"crossref","unstructured":"Li, Y., et al. (2023). The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Investigation, e14125.","DOI":"10.1111\/eci.14125"},{"key":"5107_CR26","unstructured":"Zhang, B., et al. (2023). Efficacy and safety of mazdutide in chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 2 Trial. Diabetes Care."},{"key":"5107_CR27","doi-asserted-by":"crossref","unstructured":"Goetze, A. M., et al. (2011). High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 21(7), 949\u201359.","DOI":"10.1093\/glycob\/cwr027"},{"issue":"11","key":"5107_CR28","doi-asserted-by":"publisher","first-page":"e202302131","DOI":"10.26508\/lsa.202302131","volume":"6","author":"Y Jiang","year":"2023","unstructured":"Jiang, Y., et al. (2023). Comprehensive analysis of the lysine succinylome in fish oil-treated prostate cancer cells. Life Science Alliance, 6(11), e202302131.","journal-title":"Life Science Alliance"},{"key":"5107_CR29","doi-asserted-by":"crossref","unstructured":"Kaplon, H., et al. (2023). Antibodies to watch in 2023. MAbs, 15(1), 2153410.","DOI":"10.1080\/19420862.2022.2153410"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-024-05107-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-024-05107-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-024-05107-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:13:59Z","timestamp":1744272839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12010-024-05107-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["5107"],"URL":"https:\/\/doi.org\/10.1007\/s12010-024-05107-x","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"19 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal study protocols (ASP) were approved by the Institutional Animal Care and Use Committee (IACUC) of Shanghai Junshi Biosciences Co., Ltd. (Shanghai, China), and all in vivo experiments were conducted according to IACUC guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}